Please assess the completion status of the following clinical trial:

Trial Title: The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a diagnosis of one of the following histologic types according to the WHO classification:~  * Angioimmunoblastic T-cell lymphoma~ * Extranodal NK/T-cell lymphoma,nasal type~ * Enteropathy-type T-cell lymphoma~ * Hepatosplenic gamma-delta T-cell lymphoma~ * Subcutaneous panniculitis-like T-cell lymphoma~ * Anaplastic large-cell lymphoma,T/null cell,primary systemic type~ * Peripheral T-cell lymphoma,not otherwise characterized~* Newly diagnosed,age 15-65 years.~* Complete work up for baseline evaluation and measurement (Appendix B)~* Patient's free written inform consent.~Exclusion Criteria:~* Patients with a known hypersensitivity to murine proteins or to any component of alemtuzumab.~* Patients who have received prior antilymphoma treatment with chemotherapy or radiotherapy~* Patients with poor performance status (PS;ECOG criteria of 3-4)(Appendix C).~* Serologic evidence of HCV and HCV RNA of chronic hepatitis.~* Serologic evidence of HBV and HBV RNA of chronic hepatitis.~* Patients with history of impaired cardiac status or myocardial infarction.~* Patients with serum creatinine \>= 1.8 mg/dl,bilirubin \>= 1.5 times upper limit of normal range,SGOT or SGPT \>= 3 times upper limit of normal range, unless due to tumor involvement.~* Patients with active uncontrolled infection,active non-malignant gastric or duodenal ulcer, uncontrolled diabetes mellitus or other severe medical conditions which would preclude aggressive cytotoxic chemotherapy.~* Active secondary malignancy.~* Pregnant or lactating women.~* Serious medical or psychiatric illness which prevent informed consent.~* Patients who are likely to lost to follow up (eg, unwilling or difficult to return,cannot be contacted).

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 1 Alemtuzumab

Based on this trial design, predict the completion outcome and termination type (if applicable).